{"analyses":[{"groupDescription":"For baseline P1NP","groupIds":["OG001","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0079","pValueComment":"Dunn's multiple comparisons test","statisticalMethod":"Kruskal-Wallis"},{"groupDescription":"For baseline sclerostin","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0482","pValueComment":"Dunn's multiple comparison test","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.1","value":"38.6"},{"groupId":"OG001","spread":"24.0","value":"39.5"},{"groupId":"OG002","spread":"23.1","value":"39.6"},{"groupId":"OG003","spread":"23.3","value":"39.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"Primary Outcome 2: To assess whether the novel magnetic resonance (MR) protocol and exploratory bone turnover markers can improve quantification of bone loss in patients with myeloma (new, relapsed, smouldering) and Monoclonal Gammopathy Of Uncertain Significance (MGUS) at baseline assessment, compared to Dual-energy X-ray Absorptiometry (DXA) and established bone turnover markers alone.\n\nThis particular section analysed the inter-group difference in baseline serum P1NP (Procollagen Type 1 N-terminal Propeptide) bone turnover marker levels, in patients from Groups 1a (new myeloma), 1b (relapsed myeloma), 1c (smouldering myeloma) and 2 (MGUS).","dispersionType":"Standard Deviation","groups":[{"description":"Cohort of patients recruited as new myeloma at baseline","id":"OG000","title":"Group 1a: New Myeloma"},{"description":"Cohort of patients recruited as relapsed myeloma at baseline","id":"OG001","title":"Group 1b: Relapsed Myeloma"},{"description":"Cohort of patients recruited as smouldering myeloma at baseline","id":"OG002","title":"Group 1c: Smouldering Myeloma"},{"description":"Cohort of patients recruited as MGUS at baseline","id":"OG003","title":"Group 2: MGUS"}],"paramType":"MEAN","populationDescription":"All participants recruited at baseline from Groups 1 and 2 who had successful measurement of baseline serum P1NP.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Primary Outcome 2: Quantifying Bone Loss - Inter-Group Differences in Baseline Serum P1NP (Procollagen Type 1 N-terminal Propeptide)","type":"PRIMARY","unitOfMeasure":"microgram per litre"}